Stop parsing PDFs. Get the API. Request Access

AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Fresenius SE & Co. KGaA

Investor Presentation • Oct 31, 2007

166_ip_2007-10-31_cb0f78d6-c05b-4545-a9df-4ee8c9c686f2.pdf

Investor Presentation

Open in Viewer

Opens in native device viewer

Analyst Meeting – Results Q1–3/2007

October 31, 2007

Safe HarborStatement

This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements contained in this presentation.

Agenda

Business Update

  • -Fresenius Group
  • -Fresenius Kabi
  • -Fresenius ProServe
  • -Fresenius Biotech

Financials

  • -Q1-3 and Q3/2007
  • -Outlook 2007

Fresenius Group: Update

  • -Excellent operating performance in all business segments and regions
    • Increased 2007 earnings guidance, sales adjusted to upper end of range
  • -Fresenius Medical Care: EPO dosing policies confirmed by FDA panel
    • Fresenius Kabi: strong organic revenue growth, several mid-size acquisition opportunities
    • Fresenius ProServe: strong operating margin development in both segments
  • -Fresenius Biotech: dossier filing preparation on track

Fresenius Group: Financial Results

S
l
a
e
s		 E
B
I
T		 N
i
t
e
n
c
o
m
e
/
Q
1
3
2
0
0
7
–		 €
8
3
9
0
m
,		 €
1
1
8
4
m
,		 €
2
9
8
m
h
G
t
t
t
t
r
o
w
a
c
o
n
s
a
n
t
c
u
r
r
e
n
c
y
r
a
e
s		 1
1
%
+		 %
1
7
+		 3
2
%
+
G
h
l
t
t
t
o
r
w
a
a
c
u
a
t
c
e
n
c
a
e
s
u
r
r
y
r		 7
%
+		 2
%
1
+		 2
8
%
+

Fresenius Group: Double-Digit EBIT Growth in all Business Segments

Q
3
/
2
0
0
1
7
-		 i
F
r
e
s
e
n
s
u
d
i
l
C
M
e
c
a
a
r
e		 i
F
r
e
s
e
n
s
u
b
i
K
a		 i
F
r
e
s
e
n
s
u
S
P
r
o
e
r
e
v
l
S
a
e
s
h
G
t
r
o
w		 \$
S
U
7
1
5
1
m
,
1
6
%
+		 €
1
9
4
4
m
,
6
%
+		 €
1
6
0
1
m
,
%
5
+
E
B
I
T
h
G
t
o
r
w		 \$
U
S
1
1
5
2
m
,
1
9
%
+		 €
2
2
4
m
1
4
%
+		 €
2
2
1
m
1
6
%
+

Fresenius Kabi

Fresenius Kabi: Sales Development

Q1-3/2007: € 1,494 m Highlights Q1-3/2007

Growth yoy

    • Strong organic growth in all product segments
  • Germany with 1 % organic growth
  • -Rest of Europe: above-market growth
    • Continued double-digit growth rates in Latin America and Asia-Pacific
  • -China 26 % organic growth

For detailed figures please see page 28.

Fresenius Kabi: 100 bps EBIT Margin Improvement Compared to Q1-3/2006

€
m		 /
Q
1
3
2
0
0
7
-		 /
Q
1
3
2
0
0
6
-		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 2
4
2
2
%
1
6		 2
1
3
2
%
1
5		 1
4
%
b
E
B
I
T
R
i
e
g
o
n
y
:
E
u
r
o
p
e
i
E
B
I
T
m
a
r
g
n		 2
1
5
2
1
4
%		 8
1
7
9
3
%
1		 %
1
5
i
l
I
t
t
n
e
n
a
o
n
a
r
E
B
I
T
i
m
a
r
g
n		 8
1
1
6
6
%		 2
7
1
6
6
%		 3
%
1
d
C
C
R
&
D
t
t
o
r
p
o
r
a
e
a
n
o
r
p
o
r
a
e		 5
4
-		 4
6
-		 1
7
%
i
N
t
e
n
c
o
m
e		 1
3
2		 1
0
1		 3
1
%

Fresenius Kabi: 2007 Financial Outlook Fully Confirmed

Guidance

O
i
g
a
n
c
e
e
n
e
r
r
v
u
h
t
g
o
r
w		 6
8
%
–
E
B
I
T
i
m
g
n
a
r		 6
0
6
%
1
1
5
–

Fresenius ProServe

Fresenius ProServe: Update

HELIOS

  • Hospital admissions increased by 3 % driving organic sales growth
  • Strong EBIT margin improvement market challenges successfully managed
  • Mariahilf hospital acquisition in Hamburg pending

VAMED

  • Excellent order intake of +59 %*in Q3/2007
  • Strong 4th quarter in sales, earnings and order intake expected

*Adjusted for Pharmaplan/Pharmatec divestiture

Fresenius ProServe: On Track to Achieve 2007 Sales Guidance

€
m		 Q
/
1
3
2
0
0
7
-		 Q
/
1
3
2
0
0
6
-		 C
h
a
n
g
e		 O
i
r
g
a
n
c
S
l
a
e
s		 1
6
0
1
,		 1
5
2
6
,		 5
%		 1
%
l
b
S
i
i
i
D
a
e
s
s
o
n
y
v
:
l
H
i
O
i
t
t
(
)
H
E
L
I
O
S
o
s
p
a
p
e
r
a
o
n
s		 1
3
4
8
,		 1
2
0
4
,		 1
2
%		 3
%
f
i
i
S
i
E
+
n
g
n
e
e
r
n
g
e
r
v
c
e
s
o
r
h
l
i
t
(
h
)
V
A
M
E
D
P
t
o
s
p
a
s
+
a
m
a
e
c
r		 2
5
3		 3
2
2
*		 2
%
1
-		 %
7
-
d
O
i
k
E
i
i
t
r
e
r
n
a
e
n
g
n
e
e
r
n
g
b
i
u
s
n
e
s
s		 2
4
5		 *
2
9
1		 1
6
%
-		 2
%
-

* incl. Pharmaplan and Pharmatec

Fresenius ProServe: 70 bps EBIT Margin Improvement Compared to Q1-3/2006

€
m		 Q
/
1
3
2
0
0
7
-		 Q
/
1
3
2
0
0
6
-		 C
h
a
n
g
e
E
B
I
T
E
B
I
T
i
m
a
r
g
n		 2
2
1
7
6
%		 0
1
5
6
9
%		 6
%
1
b
E
B
I
T
D
i
i
i
y
v
s
o
n
:
l
H
i
O
i
t
t
o
s
p
a
p
e
r
a
o
n
s
i
E
B
I
T
m
a
r
g
n		 1
1
1
8
2
%		 9
4
8
%
7		 1
8
%
f
h
l
E
i
i
S
i
i
t
+
n
g
n
e
e
r
n
g
e
r
v
c
e
s
o
r
o
s
p
a
s
i
E
B
I
T
m
a
r
g
n		 1
3
5
1
%		 *
1
4
%
4
5		 7
%
-
C
t
t
o
p
o
a
e
c
o
s
s
r
r		 2
-		 3
-		 3
3
%

* incl. Pharmaplan and Pharmatec

Fresenius ProServe: 2007 Earnings Outlook Raised

Fresenius Biotech

Fresenius Biotech: Update

    • On track for submission of malignant ascites dossier to EMEA end of 2007
  • removab® partnering process for North America and Japan ongoing
  • Fresenius Biotech is taking over the US-ATG-Fresenius S clinical development program from Nabi Biopharmaceuticals
    • 2007 EBIT outlook of ~ €-50 m confirmed

Fresenius Group: Poised for Continued Profitable Growth

  • Industry-leading organic growth in all business segments
  • Additional growth opportunities through acquisitions
  • International expansion as key organic growth driver for Fresenius Medical Care and Fresenius Kabi
  • Competitive advantage through state-of-the-art technologies and therapies

Group Financials Q1-3/2007 −Outlook 2007

Fresenius Group: Growth Track Continued

  • -Financial performance strongly impacted by currency translation
  • -EBIT margin at all-time high
  • -Substantial positive free cash flow
  • -Progress on net debt/EBITDA ratio

Fresenius Group: Sales Growth Analysis Q1-3/2007

Sales Q1-3/2007: € 8,390 m

  • Fresenius Medical Care: International growth of 23 %
  • Fresenius Kabi: Q3/2007 organic growth of 8 %
  • Fresenius ProServe: Strong Q4/2007 expected

Fresenius Group: Profit and Loss Statement

€
m		 Q
/
3		 Q
/
1
3
-		 Q
/
1
3
2
-		 0
0
7
Y
Y
o		 k
R
e
m
a
r
s
2
0
0
7		 2
0
0
7		 l
t
a
c
u
a
t
r
a
e
s		 t
t
c
o
n
s
a
n
t
r
a
e
s		 Q
/
1
3
2
0
0
7
-
S
l
a
e
s		 2
9
8
7
,		 8
3
9
0
,		 %
7
+		 %
1
1
+
E
B
I
T		 4
0
4		 1
1
8
4
,		 1
2
%
+		 1
7
%
+
l
I
t
t
t
n
e
r
e
s
r
e
s
u		 9
4
-		 2
9
7
-		 %
5
+		 0
%		 f
d
b
8
6
%
i
t
o
e
n
f
d
/
h
d
d
i
t
e
e
g
e
a
e
s
x
r
T
a
e
s
x		 1
1
2
-		 3
2
6
-		 %
4
-		 1
0
%
-		 3
6
0
%
t
t
a
x
r
a
e
N
i
t
e
n
c
o
m
e		 1
0
3		 2
9
8		 2
8
%
+		 3
2
%
+
f
S
(
)
(
€
)
E
P
p
e
s
r		 0
6
6		 9
3
1		 2
6
%
+		 3
0
%
+

Fresenius Group: Cash Flow

€
m		 /
Q
3
2
0
0
7		 /
Q
1
3
2
0
0
7
-		 /
Q
1
3
2
0
0
7
-
Y
Y
o		 R
k
e
m
a
r
s
/
Q
1
3
2
0
0
7
-
S
i
h
f
l
C
a
s
o
w		 3
1
0		 8
9
2		 1
9
%
+		 t
r
o
n
g
e
a
r
n
n
g
s
h
t
g
r
o
w
h
k
l
C
i
W
i
i
t
a
n
g
e
n
o
r
n
g
c
a
p
a		 4
9
+		 2
0
+		 1
1
4
%
+		 f
f
T
i
2
0
0
6
t
a
e
e
c
n
x
f
O
i
C
h
l
t
p
e
a
n
g
a
s
o
r
w		 3
9
5		 9
2
1		 %
5
5
+		 M
i
1
0
9
%
a
g
n
r
:
(
)
C
t
a
p
e
n
e
x		 1
6
8
-		 4
6
5
-		 2
9
%
-		 H
i
t
t
e
a
n
e
s
m
e
n
v
y
v
i
i
t
t
a
c
v
y
h
f
l
C
a
s
o
w
(
b
f
d
d
d
d
)
i
i
t
i
i
i
e
o
r
e
a
c
q
u
s
o
n
s
a
n
v
e
n
s		 1
9
1		 4
4
7		 9
6
%
+
(
)
A
i
i
i
t
t
c
q
u
s
o
n
s
n
e		 2
0
-		 8
2
1
-		 9
%
4
+
d
d
D
i
i
v
e
n
s		 3
-		 9
1
1
-		 2
0
%
-
h
f
l
F
C
e
e
a
s
o
r
w
(
f
d
d
d
d
)
i
i
i
i
i
t
t
a
e
a
c
q
s
o
n
s
a
n
e
n
s
r
u
v		 1
6
8		 7
4		 1
0
2
%
+

Fresenius Group: Debt and Interest Ratios

Fresenius Group: Earnings Outlook 2007 Raised

Attachments

Fresenius Kabi: Strong Sales Growth in Q3/2007 – Fully in Line with Guidance

€
m		 /
Q
1
3
2
0
0
7
–		 /
Q
1
3
2
0
0
6
-		 O
i
r
g
a
n
c
G
h
t
r
o
w
T
l
S
l
t
o
a
a
e
s		 1
4
9
4
,		 1
4
0
4
,		 7
%
d
B
P
S
t
t
y
r
o
u
c
e
g
m
e
n
:
f
h
i
I
T
n
s
o
n
e
a
p
u
r
y		 9
3
7		 6
1
7		 %
5
l
l
C
i
i
N
i
i
t
t
n
c
a
u
r
o
n		 6
1
0		 5
5
5		 1
1
%
f
h
l
T
i
T
a
n
s
s
o
n
e
n
o
o
g
r
u
c
y		 9
1		 8
8		 %
4

Fresenius Kabi: Growth in All Regions

i
l
S
l
R
e
g
o
n
a
a
e
s
€
m		 Q
/
1
3
-
2
0
0
7		 Q
/
1
3
-
2
0
0
6		 G
h
t
r
o
w		 O
i
r
g
a
n
c
G
h
t
r
o
w
G
e
m
a
n
r
y		 3
2
2		 3
1
9		 1
%		 1
%
E
u
r
o
p
e
G
e
x
e
r
m
a
n
y		 6
8
4		 6
0
5		 %
5		 %
5
f
A
i
P
i
i
s
a
a
c
c
-		 2
2
7		 1
9
0		 1
9
%		 2
2
%
L
i
A
i
t
a
n
m
e
r
c
a		 1
0
5		 9
4		 1
2
%		 1
0
%
R
W
o		 1
5
6		 1
5
1		 3
%		 0
%
1
T
l
l
t
o
a
s
a
e
s		 1
4
9
4
,		 1
4
0
4
,		 6
%		 7
%

Fresenius ProServe – Sales Impact HELIOS Hospital Acquisitions/Divestitures / Divestiture Pharmaplan/Pharmatec

HUMAINE Kliniken Group Hospital Überlingen (Lake Constance) € Hospital Oberhausen (NRW) Hospital Lengerich (NRW) Hospital Mariahilf, Hamburg

Hospital Reichenbach Hospital Herbolzheim Pharmaplan Pharmatec

Acquisitions Annualized sales

  • €~197 m consolidated as of Jul 1, 2006
  • 0~22 m consolidated as of Jan 1, 2007
  • €0~20 m consolidated as of Apr 1, 2007
  • €0~12 m consolidated as of Apr 1, 2007
  • €0~26 m not yet closed

Divestitures Annualized sales

  • €0~18 m deconsolidated as of Aug 31, 2006
  • €0~11 m deconsolidated as of Dec 31, 2006
  • €0~60 m deconsolidated as of Jan 1, 2007
  • €0~30 m deconsolidated as of June 30, 2007

Fresenius Group: Solid Balance Sheet Structure

Fresenius Group: Overview –Calculation of Minority Interest

€
m		 Q
/
1
3
2
0
0
7
-		 /
F
Y
2
0
0
6
i
G
F
e
s
e
n
s
o
p
r
u
r
u
:
b
f
d
E
i
i
i
i
t
t
t
t
a
r
n
n
g
s
e
o
r
e
a
x
a
n
m
n
o
r
y
n
e
r
e
s		 9
0
5		 1
0
4
9
,
l
l
f
O
C
i
i
M
i
i
I
t
t
t
e
e
a
c
a
o
n
o
n
o
n
v
r
v
w
u
r
y
–
T
a
e
s
x		 t
e
e
s
r
3
2
6
-		 4
1
4
-
h
f
M
i
i
i
t
t
t,
t
n
o
r
y
n
e
r
e
s
e
r
e
o		 2
8
1
-		 3
0
5
-
d
l
b
b
l
F
i
M
i
C
i
i
t
t
t
t
t
e
s
e
n
s
e
c
a
a
e
n
e
n
c
o
m
e
n
o
a
a
e
r
u
r
r
u
F
i
(
6
4
%
)
t
o
e
e
n
r
s
u
s
~		 2
4
7
-		 2
7
2
-
h
l
d
d
l
M
i
i
i
i
F
i
M
i
C
t
t
t
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
e
c
a
a
r
e
\$
\$
(
/
d
2
0
0
6
U
S
1
7
Q
1
3
2
0
0
7
U
S
2
0
i
:
m
:
m
a
c
c
o
r
n
g
-
,
i
d
i
l
C
's
i
i
l
S
)
t
F
M
F
t
t
t
o
e
e
n
e
e
n
n
e
m
e
n
r
s
u
s
c
a
a
r
a
c
a
a		 1
5
-		 1
4
-
h
l
d
b
M
i
i
i
i
F
i
K
i,
t
t
t
n
o
r
y
n
e
r
e
s
o
e
r
s
n
r
e
s
e
n
u
s
a
h
F
i
P
S
F
i
B
i
t
e
s
e
n
s
o
e
e
e
s
e
n
s
o
e
c
r
u
r
r
v
r
u
,		 1
9
-		 1
9
-
N
i
t
e
n
c
o
m
e		 2
9
8		 3
3
0

Fresenius Group: Key Figures According to IFRS

€
m		 /
Q
1
3
2
0
0
7
-
U
S
G
A
A
P		 /
Q
1
3
2
0
0
7
-
I
F
R
S
l
S
a
e
s		 8
3
9
0
,		 8
4
1
6
,
E
B
I
T		 8
1
1
4
,		 2
0
1
4
,
l
I
t
t
t
n
e
e
s
e
s
r
r
u		 2
9
7
-		 2
9
7
-
N
i
t
e
n
o
m
e
c		 2
9
8		 3
0
4
O
C
h
f
l
i
t
p
e
r
a
n
g
a
s
o
w		 9
2
1		 9
1
7
l
h
l
B
t
t
t
a
a
n
c
e
s
e
e
o
a		 1
5
0
5
4
,		 1
5
0
6
7
,

Financial Calendar

  • 20.2.2008Report on Fiscal Year 2007
  • 30.4.2008Report on 1st quarter 2008
  • 21.5.2008Annual General Meeting, Frankfurt/Main
  • 30.7.2008Report on 1st half 2008
  • 4.11.2008Report on 1st-3rd quarters 2008

Contact

Birgit Grund SVP Investor Relations Fresenius SE

Telephone: +49 6172 608-2485 e-mail:[email protected]

For further information and current news: http://www.fresenius.com

More from Fresenius SE & Co. KGaA

Declaration of Voting Results & Voting Rights Announcements 2025
Nov 17
Declaration of Voting Results & Voting Rights Announcements 2025
Nov 14
Report Publication Announcement 2025
Nov 6
Quarterly Report 2025
Nov 6
Interim / Quarterly Report 2025
Aug 6
Investor Presentation 2025
Aug 6
Declaration of Voting Results & Voting Rights Announcements 2025
Jul 4
Declaration of Voting Results & Voting Rights Announcements 2025
Jun 20
Governance Information 2025
May 23
Quarterly Report 2025
May 7
View all filings →

Talk to a Data Expert

Have a question? We'll get back to you promptly.